학술논문
Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT
Document Type
Article
Author
Vincent, Laure; Gras, Luuk; Ceballos, Patrice; Finke, Jürgen; Passweg, Jakob; Harel, Stéphanie; Rosinol, Laura; Minnema, Monique; Teipel, Raphael; van Doesum, Jaap; Hänel, Mathias; Lenain, Pascal; Botella-Garcia, Carmen; Koenecke, Christian; Ducastelle, Sophie; Sanz, Jaime; Schroyens, Wilfried; Zuckerman, Tsila; Monaco, Federico; Koster, Linda; de Wreede, Liesbeth; Hayden, Patrick J.; Schönland, Stefan; Yakoub-Agha, Ibrahim; Beksac, Meral
Source
Bone Marrow Transplantation; March 2022, Vol. 57 Issue: 3 p499-501, 3p
Subject
Language
ISSN
02683369; 14765365
Abstract
Dara post-alloHCT does not appear to increase the incidence of GVHDSuperior PFS was seen in those with prior cGvHDInfections are commonExtra-medullary disease progression is common